Psoriasis is more than a skin condition. Research has long noted that people living with chronic plaque psoriasis tend to carry a higher burden of metabolic problems, including obesity, elevated blood sugar, and unfavorable cholesterol levels. When both conditions exist together, managing one without thinking about the other often leaves important health markers untouched.
A prospective observational study published in Dermatology and Therapy set out to measure exactly what happens to a range of metabolic markers when adults with both psoriasis and obesity receive a dual GIP/GLP-1 receptor agonist peptide called tirzepatide. The peptide works by activating two separate hormonal pathways that the body normally uses to regulate blood sugar and appetite. The study followed 64 adults over 24 weeks and documented changes in body weight, waist measurements, fasting glucose, cholesterol fractions, triglycerides, liver enzymes, and kidney function.
This article walks through what the researchers measured, what they found, and why the intersection of skin disease and metabolic health is drawing increasing scientific attention.
Study design and participants
All 64 participants in the study had confirmed chronic plaque psoriasis and a body mass index at or above 30, the standard clinical threshold for obesity. Every participant was already receiving stable therapy with ixekizumab, a biologic treatment targeting a specific inflammatory protein involved in psoriasis. This design meant researchers could observe the metabolic effects of adding the peptide on top of an existing, steady treatment rather than sorting through the effects of multiple new variables at once.
Participants started on a low dose of 2.5 milligrams of tirzepatide per week, which was then titrated upward to 5 milligrams weekly. Anthropometric measurements, meaning body weight, BMI, and waist-to-hip ratio, were collected at baseline and again at the 24-week mark. Blood draws captured fasting glucose, a full lipid panel, liver enzyme levels, and kidney function markers. The Psoriasis Area and Severity Index, a standard scoring tool dermatologists use to quantify how much of the skin is affected and how severely, was also recorded at both time points.
Weight and body composition findings
By week 24, the group showed a statistically significant average reduction in body weight of 10 percent. BMI dropped by an average of 3.5 units. Waist-to-hip ratio, which researchers use as a proxy for how fat is distributed around the abdomen and organs rather than under the skin, fell by 8 percent. All three changes reached the threshold for statistical significance at p less than 0.001, meaning the probability that these results occurred by chance alone is extremely low.
Visceral adiposity indices, calculated measures that estimate the amount of fat surrounding internal organs, also shifted in a favorable direction. Visceral fat is considered particularly relevant in metabolic research because it is more metabolically active than fat stored beneath the skin and is associated with a wider range of downstream effects on blood sugar regulation and inflammation.
Blood sugar and lipid profile changes
Fasting blood glucose, the amount of sugar circulating in the blood after an overnight fast, decreased by 11.9 percent from baseline. This measurement is frequently used in research as a window into how efficiently the body is processing glucose when no food is present.
The lipid panel results were similarly notable. Low-density lipoprotein cholesterol, often referred to in shorthand as LDL, fell by 6.7 percent. Triglycerides, a type of fat that circulates in the blood and is closely tied to dietary carbohydrate intake and liver metabolism, decreased by 15.4 percent. Both changes were statistically significant. High-density lipoprotein, the cholesterol fraction sometimes described in lay terms as protective, was not reported as changing significantly in the abstract.
Taken together, these lipid findings align with a broader pattern seen in the literature on GLP-1 receptor agonist peptides, where reductions in overall body fat appear to coincide with shifts in circulating fats. The dual GIP pathway that tirzepatide activates is thought to add incremental effects on fat metabolism beyond what single-receptor agonists achieve.
Liver enzyme and kidney function results
Two liver enzymes, aspartate aminotransferase and alanine aminotransferase, are routinely measured to give a rough picture of liver stress or inflammation. In this study, aspartate aminotransferase dropped by 12.4 percent and alanine aminotransferase by 11.6 percent. Elevated liver enzymes are common in people with obesity, partly because excess fat can accumulate in liver tissue, a condition often called metabolic-associated fatty liver disease in research literature.
Renal function markers, used to assess how well the kidneys are filtering waste from the blood, remained stable over the 24-week period. The researchers interpreted this as a sign that the peptide did not place additional burden on kidney function at these doses, which is a relevant consideration when studying any compound in a population that already carries metabolic risk.
Psoriasis severity scores
Perhaps the most striking single number in the study was the change in Psoriasis Area and Severity Index scores. At baseline, the average score across participants was 4.2, indicating mild to moderate disease activity. By week 24, that average had fallen to 1.01, representing a 76 percent reduction. This change was statistically significant at p less than 0.001.
The authors were careful not to claim that the peptide treated psoriasis directly. All participants remained on their biologic therapy throughout the study. The authors noted that because the peptide was added alongside an already stable treatment, and because psoriasis is known to be closely connected to systemic inflammation and metabolic dysfunction, the weight loss and metabolic improvements may have contributed indirectly to reduced disease activity. Early data points at a bidirectional relationship: metabolic stress can worsen inflammatory skin conditions, and reducing that metabolic burden may help existing treatments work more effectively. However, the study design cannot separate the effects of the two treatments on skin outcomes.
What the researchers concluded
The authors of the study concluded that even at relatively low doses, tirzepatide produced clinically meaningful improvements across multiple metabolic parameters in this specific population. They framed the findings as evidence that this type of dual-receptor peptide therapy could have a role within a broader metabolic management strategy for people managing both psoriasis and obesity simultaneously.
The study had real-world design strengths, including that it captured what actually happens in a clinical setting rather than under the tightly controlled conditions of a randomized controlled trial. At the same time, the absence of a placebo group and the concurrent use of a biologic medication means that attributing specific outcomes to either treatment alone is not straightforward. The authors acknowledged these limitations and called for further controlled research.
For researchers and science-minded readers, the study adds to a growing body of literature suggesting that the metabolic and inflammatory dimensions of psoriasis are deeply connected, and that peptides acting on hormonal pathways involved in energy and glucose regulation may produce effects that extend beyond simple weight reduction. The literature suggests this intersection of dermatology and metabolic medicine is an area where future clinical investigation is likely to expand.
